Castle Biosciences Q1 2026 Earnings EPS Beat Slightly Narrower Loss Stock Rises 26 VISN Q1 2026 Earnings Earnings Surge Past Estimates with 7094 EPS Beat CVKD Q1 2026 Earnings Narrowing Losses and Steady Progress in Clinical Pipeline Home Sellers Question Commission Rates PostNAR Settlement Will the 6 Standard Shift Outset Medical Q1 2026 Earnings EPS Misses Estimates as Stock Edges Lower AERT Q1 2026 Earnings A Modest Profit as Aeries Technology Navigates Early Growth Phase ON24 Q4 2025 Earnings Strong EPS Beat Drives Stock Higher Amid Revenue Disclosure Gap